News

CLINUVEL
Posted by CLINUVEL
March 17, 2023

DNA Repair data presented at American Academy of Dermatology Meeting

First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...

Read More
CLINUVEL
Posted by CLINUVEL
March 13, 2023

Statement on Silicon Valley Bank (SVB)

Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
Lachlan Hay
Posted by Lachlan Hay
March 10, 2023
CLINUVEL
Posted by CLINUVEL
March 10, 2023

News Communiqué I - Maestro Jaap van Zweden

Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.

Read More
Lachlan Hay
Posted by Lachlan Hay
March 9, 2023

Commercial Update SCENESSE®

CLINUVEL today published its 2022 status report on the commercial distribution of...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2023

Relief from Quarterly Reporting

Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
March 1, 2023

CLINUVEL launches CYACÊLLE, Next Generation Solar Care

Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
March 1, 2023

CYACÊLLE Polychromatic Solar Care – λ3

Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 28, 2023

Proposed issue of Securities

Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2023

Global SCENESSE® demand drives increased CLINUVEL revenues, earnings

Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2023

Appendix 4D Half Yearly Report

Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 14, 2023

PRÉNUMBRA® Formulation Completed For Clinical Trial Use

CLINUVEL today announced the completion of manufacture of the first cGMP batch...

Read More
CLINUVEL
Posted by CLINUVEL
February 9, 2023

Chair's Letter

Melbourne, Australia, 09 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 2, 2023

Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note

Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 2, 2023

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

Results released today from a clinical study have shown that the drug...

Read More